The American Dietetic Association commends Congress for passing a three-year reauthorization of the Ryan White CARE Act, the largest federal program specifically for people with HIV and AIDS, with new attention to the unique dietary needs of patients.
The National Institutes of Health (NIH) launched a new website today offering technologies available for commercial licensing that are related to rare diseases or conditions. The listing can be found at http://www.ott.nih.gov/rarediseases and currently consists of more than 500 such technologies, including drugs, biologics, and devices, available to be transferred from the NIH and the U.S. Food and Drug Administration (FDA) to the private sector for further research and development and potential commercialization.
Agriculture Secretary Mike Johanns today awarded nearly $1 million to 14 faith-based and community organizations for their efforts to improve access to, and awareness of, USDA’s Food Stamp Program for eligible low-income households.
Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. today announced the launch of ABILIFY? (aripiprazole) Injection, an injectable form of ABILIFY, for intramuscular use. ABILIFY Injection provides rapid control of agitation in adults with schizophrenia or bipolar mania at primary endpoint (2 hours).
Today, Bristol-Myers Squibb Company (NYSE: BMY) announced results from a randomized Phase III study showing that patients receiving SPRYCEL 100 mg once a day achieved similar cytogenetic responses at six months with considerably fewer hematologic and non-hematologic adverse events than patients receiving three other dosing schedules of SPRYCEL.
Eli Lilly and Company (NYSE: LLY) announced today that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration’s Division of Drug Oncology Products (DDOP) for EVISTA? (raloxifene HCl) for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for breast cancer.
New clinical data presented today demonstrated that Tasigna? (nilotinib) eliminated or significantly reduced the presence of blood cells containing a defective chromosome in approximately half of adult patients with a form of life-threatening leukemia who developed resistance or intolerance to treatment with Glivec? (imatinib).
The Food and Drug Administration is continuing its investigation of an outbreak of E. coli O157:H7 infections linked to eating food from Taco Bell restaurants in 5 states. FDA is collaborating with state and local health officials, the U.S. Centers for Disease Control and Prevention (CDC), and the firm to identify the cause of the outbreak.
The U.S. Food and Drug Administration (FDA) is currently working with five states and the Centers for Disease Control and Prevention to investigate an outbreak of norovirus which has been associated with raw, frozen oysters on the half shell from South Korea.
The Food and Drug Administration (FDA) today ordered firms to stop marketing unapproved drug products containing quinine, a drug used to treat malaria, citing serious safety concerns, including deaths, associated with quinine products. There are multiple unapproved products containing quinine currently marketed. However, there is only one quinine product approved by the FDA.